Virginia Commonwealth University will radically expand treatment options for liver and liver-related metabolic diseases thanks to a historic, transformational $104 million gift from Richard Todd Stravitz, M.D., and his family's Barbara Brunckhorst Foundation.
(1)
Circulating cell-free mRNA in blood reflective of NAFLD/NASH liver pathology
PALO ALTO, Calif., Feb. 23, 2021 /PRNewswire/ Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human proof-of-concept study describing the stratification of NAFLD/NASH patients with clinically relevant and advanced liver fibrosis using the company s Next-Generation cell-free mRNA Liquid Biopsy Technology Platform. The study titled Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization was published in the
American Journal of Physiology -
Gastrointestinal and Liver Physiology, a journal of the American Physiological Society. The first author is Naga Chalasani, M.D., Professor of Gastroenterology and Hepatology and Interim Chair in the Department of Medicine at Indiana University in the USA. Dr. Chalasani is the leading author of the AASLD Practice Guidelines for the diagnosis and